secwatch.observer — SEC 8-K summary
======================================

Issuer:     Structure Therapeutics Inc. (GPCR)
CIK:        0001888886
Form:       8-K
Filed at:   2023-08-10T23:59:59+00:00
Accession:  0001104659-23-089815
Event type: earnings
Sentiment:  neutral
Materiality: 0.50
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Structure Therapeutics reports Q2 net loss $23.3M; completes Phase 2a enrollment for GSBR-1290
--------------------------------------------------------------------------------

- Net loss of $23.3M for Q2 2023 vs $15.5M for Q2 2022; includes $1.7M stock-based compensation.
- Cash, equivalents and short-term investments of $224.6M at June 30, 2023; expected to fund operations through at least 2025.
- R&D expenses $19.4M for Q2 2023 vs $10.2M in Q2 2022, driven by GLP-1R franchise advancement.
- Completed enrollment in 12-week Phase 2a study of oral GLP-1 agonist GSBR-1290 (94 participants); topline data expected latter half Q4 2023.
- Appointed Ted W. Love, M.D. to Board of Directors; preparations underway for global Phase 2b study in 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1888886/000110465923089815/0001104659-23-089815-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1888886/000110465923089815/tm2323266d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-089815

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer